Sensus Healthcare Announces Publication of Study at Tri Service Military Hospital in Taiwan Demonstrating Efficacy of SRT-100® in Preventing Keloid Recurrence
Sensus Healthcare (NASDAQ: SRTS) has announced the publication of a significant study in the Annals of Plastic Surgery demonstrating the effectiveness of their SRT-100® system in preventing keloid recurrence. The study, conducted at Tri Service Military Hospital in Taiwan, evaluated the combination of surgical keloid excision with primary wound closure followed by Superficial Radiation Therapy (SRT).
The research, involving 12 patients with 16 keloids, showed no keloid recurrence in most patients during follow-up periods exceeding six months. This marks Sensus Healthcare's first study in Asia, with the hospital utilizing the SRT-100® since 2023.
The study's results are particularly significant as keloids, which are benign skin tumors caused by abnormal scar tissue growth, traditionally show high recurrence rates with conventional treatments like corticosteroid injections, cryotherapy, and laser therapy. The integration of SRT targets excess fibroblast activity, addressing the root cause of keloid regrowth.
Sensus Healthcare (NASDAQ: SRTS) ha annunciato la pubblicazione di uno studio significativo negli Annals of Plastic Surgery che dimostra l'efficacia del loro sistema SRT-100® nella prevenzione della ricorrenza dei cheloidi. Lo studio, condotto presso il Tri Service Military Hospital di Taiwan, ha valutato la combinazione di escissione chirurgica del cheloide con chiusura primaria della ferita seguita da Terapia Radioterapica Superficiale (SRT).
La ricerca, che ha coinvolto 12 pazienti con 16 cheloidi, non ha mostrato ricorrenza dei cheloidi nella maggior parte dei pazienti durante i periodi di follow-up superiori ai sei mesi. Questo segna il primo studio di Sensus Healthcare in Asia, con l'ospedale che utilizza il SRT-100® dal 2023.
I risultati dello studio sono particolarmente significativi poiché i cheloidi, che sono tumori benigni della pelle causati da una crescita anomala del tessuto cicatriziale, mostrano tradizionalmente alti tassi di ricorrenza con trattamenti convenzionali come iniezioni di corticosteroidi, crioterapia e terapia laser. L'integrazione della SRT mira a ridurre l'attività eccessiva dei fibroblasti, affrontando la causa principale della ricrescita del cheloide.
Sensus Healthcare (NASDAQ: SRTS) ha anunciado la publicación de un estudio significativo en los Annals of Plastic Surgery que demuestra la efectividad de su sistema SRT-100® en la prevención de la recurrencia de queloides. El estudio, realizado en el Tri Service Military Hospital en Taiwán, evaluó la combinación de la excisión quirúrgica del queloide con el cierre primario de la herida seguido de Terapia de Radiación Superficial (SRT).
La investigación, que involucró a 12 pacientes con 16 queloides, no mostró recurrencia de queloides en la mayoría de los pacientes durante los períodos de seguimiento que superaron los seis meses. Este es el primer estudio de Sensus Healthcare en Asia, con el hospital utilizando el SRT-100® desde 2023.
Los resultados del estudio son particularmente significativos ya que los queloides, que son tumores benignos de la piel causados por un crecimiento anormal del tejido cicatricial, tradicionalmente muestran altas tasas de recurrencia con tratamientos convencionales como inyecciones de corticosteroides, crioterapia y terapia láser. La integración de la SRT se enfoca en la actividad excesiva de los fibroblastos, abordando la causa raíz del crecimiento del queloide.
Sensus Healthcare (NASDAQ: SRTS)는 SRT-100® 시스템의 켈로이드 재발 방지 효과를 입증하는 중요한 연구 결과를 성형외과 연보에 발표했다고 발표했습니다. 대만의 삼군병원에서 실시된 이 연구는 외과적 켈로이드 절제와 1차 상처 봉합 후 표면 방사선 치료(SRT)의 조합을 평가했습니다.
12명의 환자와 16개의 켈로이드를 포함한 이 연구는 6개월 이상 추적 관찰 기간 동안 대부분의 환자에서 켈로이드 재발이 없음을 보여주었습니다. 이는 Sensus Healthcare의 아시아 첫 연구로, 해당 병원은 2023년부터 SRT-100®을 사용하고 있습니다.
연구 결과는 특히 중요합니다. 켈로이드는 비정상적인 흉터 조직 성장으로 인해 발생하는 양성 피부 종양으로, 전통적으로 스테로이드 주사, 냉동 요법 및 레이저 치료와 같은 기존 치료법으로 높은 재발률을 보입니다. SRT의 통합은 과도한 섬유아세포 활동을 겨냥하여 켈로이드 재성장을 유발하는 근본 원인을 해결합니다.
Sensus Healthcare (NASDAQ: SRTS) a annoncé la publication d'une étude significative dans les Annals of Plastic Surgery démontrant l'efficacité de leur système SRT-100® dans la prévention de la récidive des chéloïdes. L'étude, réalisée au Tri Service Military Hospital à Taïwan, a évalué la combinaison de l'excision chirurgicale du chéloïde avec la fermeture primaire de la plaie suivie d'une thérapie de radiation superficielle (SRT).
La recherche, impliquant 12 patients avec 16 chéloïdes, n'a montré aucune récidive chez la plupart des patients pendant des périodes de suivi dépassant six mois. Cela marque la première étude de Sensus Healthcare en Asie, l'hôpital utilisant le SRT-100® depuis 2023.
Les résultats de l'étude sont particulièrement significatifs car les chéloïdes, qui sont des tumeurs bénignes de la peau causées par une croissance anormale du tissu cicatriciel, présentent traditionnellement des taux de récidive élevés avec des traitements conventionnels tels que les injections de corticostéroïdes, la cryothérapie et la thérapie au laser. L'intégration de la SRT cible l'activité excessive des fibroblastes, s'attaquant à la cause profonde de la régénération des chéloïdes.
Sensus Healthcare (NASDAQ: SRTS) hat die Veröffentlichung einer bedeutenden Studie in den Annals of Plastic Surgery bekannt gegeben, die die Wirksamkeit ihres SRT-100® Systems zur Verhinderung von Keloid-Rückfällen demonstriert. Die Studie, die im Tri Service Military Hospital in Taiwan durchgeführt wurde, bewertete die Kombination aus chirurgischer Keloidexzision mit primärem Wundverschluss, gefolgt von oberflächlicher Strahlentherapie (SRT).
Die Forschung, an der 12 Patienten mit 16 Keloiden beteiligt waren, zeigte bei den meisten Patienten während der Nachbeobachtungszeiträume von über sechs Monaten keine Keloid-Rückfälle. Dies markiert die erste Studie von Sensus Healthcare in Asien, wobei das Krankenhaus das SRT-100® seit 2023 einsetzt.
Die Ergebnisse der Studie sind besonders bedeutend, da Keloide, die gutartige Hauttumoren sind, die durch abnormales Wachstum von Narbengewebe verursacht werden, traditionell hohe Rückfallraten bei herkömmlichen Behandlungen wie Kortikosteroid-Injektionen, Kryotherapie und Lasertherapie aufweisen. Die Integration von SRT zielt darauf ab, die übermäßige Fibroblastenaktivität zu reduzieren und damit die Hauptursache für das Wiederaufleben von Keloiden anzugehen.
- First successful clinical validation in Asian market
- 100% success rate in preventing keloid recurrence
- Publication in prestigious peer-reviewed journal validates technology
- Small study size (only 12 patients)
- follow-up period (6+ months)
Insights
Sensus Healthcare's recent publication in the Annals of Plastic Surgery represents a significant clinical validation for their SRT-100® system in the treatment of keloids. The retrospective study demonstrated 100% efficacy in preventing keloid recurrence when superficial radiation therapy was used following surgical excision - a meaningful outcome considering the traditionally high recurrence rates with conventional treatments.
The study, though relatively small with 12 patients and 16 keloids, establishes an important clinical foothold in the Asian market where keloid prevalence is higher among southeast Asian populations. This geographic relevance is particularly noteworthy as it marks Sensus's first published research in Asia, conducted at Taiwan's Tri Service Military Hospital which has been using the system since 2023.
From a clinical perspective, keloid management presents persistent challenges for dermatologists and plastic surgeons, with traditional approaches like corticosteroid injections, cryotherapy, and laser therapy delivering inconsistent results. The publication demonstrates that SRT-100® targets the underlying pathophysiology - excessive fibroblast activity - without requiring invasive interventions, potentially positioning it as a preferred treatment protocol for this difficult-to-treat condition.
While this publication won't drive immediate revenue shifts for this
The single-site, retrospective study evaluated the clinical outcomes of combining surgical excision of keloids with primary wound closure followed by adjuvant Superficial Radiation Therapy (SRT) using Sensus Healthcare's SRT-100® system. The findings from follow-up visits involving 12 patients with 16 keloids indicate that no keloid recurrence was observed with most patients followed for more than six months, highlighting the efficacy of this treatment approach. This is Sensus Healthcare’s first study in
"We are delighted to see the SRT-100® system featured in this prestigious peer-reviewed publication, further validating its role in keloid management," said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. "Keloids can be both physically and emotionally distressing for patients, and traditional treatment approaches often lead to high recurrence rates with even-larger keloids. By integrating SRT following surgical excision, we provide a non-invasive, targeted solution that significantly reduces recurrence and improves patient outcomes. This study reinforces our commitment to advancing clinically proven therapies that enhance quality of life for those suffering from dermatological issues including keloids, which are relatively more prevalent in southeast Asian populations."
Keloids are benign skin tumors that develop due to an abnormal overgrowth of scar tissue, often extending beyond the original wound site. They can cause significant discomfort, itching and even pain, in addition to the cosmetic concerns that may lead to emotional distress. Traditional treatment options, including corticosteroid injections, cryotherapy and laser therapy, often yield inconsistent results and are associated with high recurrence rates.
This study suggests the integration of SRT as an adjunct to surgical excision provides an improved treatment regimen by targeting the root cause of keloid regrowth—excess fibroblast activity—without invasive procedures or prolonged recovery periods. The study's findings further support SRT's ability to significantly reduce recurrence, offering patients a more reliable and effective long-term solution.
The study is accessible online in the March 2025 issue of the Annals of Plastic Surgery.
About Sensus Healthcare
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “approximately,” "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release, as a result of the following factors, among others: the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the
Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250304134583/en/
Alliance Advisors IR
Tirth T. Patel
tpatel@allianceadvisors.com
212-201-6614
Source: Sensus Healthcare, Inc.
FAQ
What were the results of the SRTS keloid treatment study in Taiwan?
How does the SRTS SRT-100® system treat keloids differently from traditional methods?
When did Tri Service Military Hospital start using SRTS's SRT-100® system?
Where was the SRTS keloid treatment study published?
